Graham Walter Warren, MD, PhD

Write a Review843-792-3271

Graham Warren, M.D. Ph.D. is a board-certified radiation oncologist, vice chairman for research in the Department of Radiation Oncology, and the Mary Gilbreth Endowed Chair of Clinical Oncology in Hollings Cancer Center at the Medical University of South Carolina (MUSC). His primary clinical emphasis is in the treatment of gastrointestinal and thoracic malignancies and he has served as the medical director for tobacco at MUSC and Roswell Park Cancer Institute. Dr. Graham works with several local, regional, national, and international organizations to increase access to evidence-based tobacco cessation support for cancer patients. He is an expert advisor for the Canadian Partnership Against Cancer (CPAC) and works with the National Institutes of Health to implement strategies to address tobacco use across cancer care and has served as a chair and/or member on tobacco or prevention committees for the American Society for Clinical Oncology (ASCO), American Association for Cancer Research (AACR), International Association for the Study of Lung Cancer (IASLC), Society for Research on Nicotine and Tobacco (SRNT),and economic effects of tobacco on cancer treatment outcomes including identifying critical biologic targets to improve therapeutic outcomes in cancer patients exposed to tobacco, National Lung Cancer Roundtable, National Cancer Institute (NCI), and the Alliance for Clinical Trials in Oncology Cooperative Group. He was a contributor for the 2014 Surgeon General’s Report on Tobacco providing the foundational work demonstrating that smoking by cancer patients and survivors causes adverse cancer treatment outcomes. He was a contributor for the 2020 Surgeon General’s Report demonstrating that smoking cessation after a cancer diagnosis improves survival in cancer patients. His work has been used to develop tobacco treatment programs for cancer patients at the institutional, regional, statewide, national, and international level including cessation initiatives across Canadian Provinces and Territories and for the NCI Cancer Center Cessation Initiative (C3I) P30 supplement distributed across NCI Designated Cancer Centers. As the vice chairman for research, he helps to coordinate research activities within the Department of Radiation Oncology, to support integration of existing research trials and to facilitate investigator initiated research projects. His primary research interest is in evaluating the biologic, clinical, behavioral, and optimizing behavioral and clinical methods to optimize data collection that can be used for clinical decision making and research.